Analytical Method Development and Validation for Estimation of Brisoprolol Fumerate in Bulk and Pharmaceutical Dosage Form by UV Spectrometric Method

Authors

  • Swati S Rawat Student, Department of Pharmacy, SND College of Pharmacy, Yeola, Nashik, Maharashtra, India
  • Ganesh Dewan Student, Department of Pharmacy, SND College of Pharmacy, Yeola, Nashik, Maharashtra, India

DOI:

https://doi.org/10.37591/rrjodfdp.v9i1.1158

Keywords:

UV Spectroscopy, Method Development, Validation, Brisoprolol Fumerate and ICH Guideline.

Abstract

The objective of the present work is to develop a new, rapid, simple, economical, precise, sensitive, linear and accurate, UV Spectrophotometric method has been developed. Phosphate buffer of pH 6.8 is used as solvent for the estimation of Brisoprolol Fumerate bulk and pharmaceutical formulation as per ICH guidelines. Spiked Brisoprolol Fumerate was checked over UV-visible extend for its wavelength of greatest absorbance. The wavelength of most extreme absorbance for Brisoprolol Fumerate was found to be 223nm. The relationship coefficient over the concentration extends of 10–50 µg/ml was found to be 0.997. The accuracy was carried out as per recovery study and found between 99.65%% to 100.45%The LOD and LOQ of Brisoprolol Fumerate was found to be 0.283 and 0.858 respectively. The method was successfully applied to estimate Brisoprolol Fumerate in prepared formulation and result were in good agreement with claims. Depending on the results, the given method can be successfully applied in estimation of Brisoprolol Fumerate.

References

Harvey, D. (2000) Modern Analytical Chemistry, 1st edition, McGraw-Hill Publication, Kingsport-USA, pg 1–2.

Skoog, D. A. et al. (2001) Principles of Instrumental Analysis, 5th edition, Thomson Books, Delhi, 11–16.

Pratik, P. et al. (2012) Spectrophotometric method Development and Validation for estimation of alpha lipoic acid in tablet dosage form, Intl J of Pharmaand Pharm sci., 5, 519–522.

Rawat, S. & Gupta, A. (2011) Regulatory Requirements for Drug Development and Approval in United States: A Review, Asian J. Pharm. Res, 1 (1), 01–06.

Rawat, S. & Gupta, A. (2011) Development of Novel HPTLC Method for Estimation of Qurcetine in Ocimum sanctum, Asian J. Pharm. Tech, 1 (4), 149–151.

Saengsirisuwan, V., Perez F.R., Sloniger, J. A., Maier, T., Henriksen, E.J. (2004) Interaction of exercise training and α-lipoic acid on insulin signaling in skeletal muscle of obese Zucker rats, Am. J. Physiol. Endocrinol. Metab., 287 (3): 529–536.

Burke, D.G., Chilibeck, P.D., Parise, G., Tarnopolsky, M.A., Candow, D.G. (2003) Effect of α-lipoic acid combined with creatine monohydrate on human skeletal muscle creatine and phosphagen concentration, Int. J. Spot. Nutr. Exerc. Metab., 13 (3): 294–302.

Evans, J.L., Heymann, C.J., Goldfine, I.D., Gravin, L.A. (2007) Antioxicants: Do they have a role in the treatment of insulin resistance? Antioxidants and Insulin resistance: Clinical studies, The Ind J Med Res., 125 (3): 360–61.

Suvarna, G. Bhokare, and Marathe, R.P. (2018) Novel Analytical Method Development and Validation for Estimation of Clinical Important Simvastatin in Bulk and Pharmaceutical Dosage Form by UV Spectrometric Method Using Phosphate Buffer Solubility, J. Biol. Chem. Chron., 4 (3), 17–23.

Thorat, S.S. and Gupta, A. (2018) Basic Concept of Stability Profile and Stress Degradation Pathway of Pharmaceutical Formulations: A Review, J. Biol. Chem. Chron., 4 (3), 34–42

British Pharmacopoeia (2009) The Department of Health, British Pharmacopoeia Commission, London, Vol. 2, pg 1410–1412.

Manohar. A. Potdar. Pharmaceutical quality assurance. Nirali prakashan,2nd edition 2010. page no: 8.1–8. 108.

Downloads

Published

2022-05-13

Issue

Vol. 9 No. 1 (2022)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.